SCHEMBL2004047

SCHEMBL2004047

NC1(C(=O)O)CCCCN1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 2/20 0.33
ARG2 P78540 1/20 0.33
CYP2C19 P33261 1/20 0.31
NSD2 O96028 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103050 0.93
SCHEMBL16585834 0.93
SCHEMBL3407152 0.93
SCHEMBL13762916 0.74
SCHEMBL22793161 0.73
SCHEMBL3934353 0.71 ARG1 (0.34) ARG1ARG2CYP2C19
SCHEMBL5492948 0.71 ARG1 (0.32) ARG1CYP2C19
SCHEMBL27486977 0.70 NSD2 (0.35) ARG1ARG2CYP2C19NSD2
SCHEMBL562022 0.70 ARG1 (0.33) ARG1ARG2CYP2C19
SCHEMBL19718510 0.70 ARG1 (0.30) ARG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12576169-B2 Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof Technische Universität München (DE) 2026-03-17 US claimed
US-20220096669-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF Technische Universität München (DE) 2022-03-31 US claimed
EP-3917581-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF Technische Universität München (DE) 2021-12-08 EP claimed
CN-113677375-A Fluorinated silicon receptor substituted radiopharmaceuticals and precursors thereof 慕尼黑工业大学 2021-11-19 CN claimed
WO-2020157128-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF Technische Universität München (DE) 2020-08-06 WO claimed
US-12576169-B2 Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof Technische Universität München (DE) 2026-03-17 US disclosed
CN-113677375-B Silicon fluoride receptor substituted radiopharmaceuticals and precursors thereof 慕尼黑工业大学 2024-07-23 CN disclosed
US-20220096669-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF Technische Universität München (DE) 2022-03-31 US disclosed
EP-3917581-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF Technische Universität München (DE) 2021-12-08 EP disclosed
CN-113677375-A Fluorinated silicon receptor substituted radiopharmaceuticals and precursors thereof 慕尼黑工业大学 2021-11-19 CN disclosed
WO-2020157128-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF Technische Universität München (DE) 2020-08-06 WO disclosed
EP-2113513-B1 Metastin derivatives and use thereof TAKEDA PHARMACEUTICAL (JP) 2016-05-18 EP disclosed
US-20090099334-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-16 US disclosed
US-20090093615-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-09 US disclosed
US-20080312155-A1 Metastin Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1963362-A1 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-09-03 EP disclosed
WO-2007072997-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 WO disclosed
CN-1972959-A Metastin derivative and use thereof TAKEDA PHARMACEUTICAL (JP) 2007-05-30 CN disclosed
EP-1758932-A2 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-03-07 EP disclosed
WO-2006001499-A2 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220096669-A1 SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF FOLH1, KLK3, FRS2 ARG1 1035/4885ARG2 2266/4885CYP2C19 3894/4885
US-20080312155-A1 Metastin Derivatives and Use Thereof GNRHR, SHBG, MEN1 ARG1 1070/4885ARG2 3055/4885CYP2C19 3968/4885
US-20090099334-A1 METASTIN DERIVATIVES AND USE THEREOF SHBG, GNRHR, INHA ARG1 764/4885ARG2 2544/4885CYP2C19 2703/4885
US-12576169-B2 Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof KLK3, FOLH1, SLC7A1 ARG1 1695/4885ARG2 2831/4885CYP2C19 4427/4885
US-20090093615-A1 METASTIN DERIVATIVES AND USE THEREOF SHBG, GNRHR, INHA ARG1 764/4885ARG2 2544/4885CYP2C19 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.